NCIC Clinical Trials Group - Canadian Collaborating Clinical Trials Network

Richard Aplenc

Genetic Predictors of AML Treatment Response

Leukaemia

Hematology and hematologic malignancies Pediatric oncology or childhood cancer

Leona W Ayers

Mid-Region Aids and Cancer Specimen Resource Consortium

Non-Hodgkin lymphoma

Hematology and hematologic malignancies Pathology

Stephanie J Lee

Improving Outcomes Assessment in Chronic Graft versus Host Disease

Non-Hodgkin lymphoma Multiple myeloma and immunoproliferative diseases Leukaemia

Hematology and hematologic malignancies

Charles D Blanke

SWOG Network Group Operations Center of the NCTN

Non-Hodgkin lymphoma Cervix uteri Brain, nervous system Corpus uteri Colorectum Stomach Leukaemia Multiple myeloma and immunoproliferative diseases Pancreas Bladder Oesophagus Liver and intrahepatic bile ducts Trachea, bronchus and lung Breast Kidney, renal pelvis and ureter Prostate Ovary

Monica M Bertagnolli

Alliance for Clinical Trials in Oncology Operations Center

Brain, nervous system Non-Hodgkin lymphoma Liver and intrahepatic bile ducts Multiple myeloma and immunoproliferative diseases Oesophagus Bladder Pancreas Leukaemia Colorectum Prostate Kidney, renal pelvis and ureter Breast Trachea, bronchus and lung

Hematology and hematologic malignancies

Susan J Ramus

Identifying Prognostic Markers and Therapeutic Targets for Serous Ovarian Cancer

Ovary

Pathology

Karin L Gaensler

Efficacy and Safety of Novel CD80 IL15 IL15Ra Expressing Autologous AML Vaccines

Leukaemia

Hematology and hematologic malignancies

David A Fruman

TOR Kinase Inhibitors for Leukemia Therapy: Mechanisms of Action and Resistance

Leukaemia

Pathology Hematology and hematologic malignancies

Reuben Kapur

Role of p21 Activated Kinase in Leukemogenesis

Leukaemia

Hematology and hematologic malignancies